ERBB2 and breast carcinoma: Three oncology drugs were selected as blockbuster drugs in the “2020 Cortellis Drugs to Watch,” two of which were ADCs for solid tumors, including SG for triple‐negative breast cancer patients and T‐DXd for HER2‐positive breast cancer patients.154